Micro Aftermath Active

Johnson & Johnson (JNJ) Benefits from Growth Pipeline and Strength Across Key Therapeutic Areas

Activity declining — narrative losing relevance.

Score
0.3
Velocity
▲ 0.0
Articles
47
Sources
3

Top Movers

TickerSectorChange
J
Industrials+16.7%
JNJ
Healthcare+9.3%

Sentiment Timeline

Sector Performance

Stock Performance

Event Timeline

Jul 19, 2026
Is It Too Late to Buy Johnson & Johnson After Its Blowout … Bullish
Jul 16, 2026
Is Johnson & Johnson a Buy After Its Latest Earnings Report? Bearish
Jul 15, 2026
J&J quarterly earnings beat Wall Street estimates on strength of medicines unit Bullish
Jul 14, 2026
Johnson & Johnson has a chance to show it's more than just … Neutral
Jul 13, 2026
The Real Case for Buying Johnson & Johnson (JNJ) Before July 15 Bullish
Jul 09, 2026
Jim Cramer Says Johnson & Johnson “Will Have Lots of Good News … Bullish
Jul 04, 2026
Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. … Neutral
Jun 26, 2026
Why Johnson & Johnson Stock Popped on Friday Bullish
Jun 22, 2026
How Johnson & Johnson (JNJ) Is Using U.S. Manufacturing Investment to Strengthen … Bullish
Jun 19, 2026
Johnson & Johnson to Invest Over $1 Billion in Florida Contact Lens … Neutral
Jun 16, 2026
J&J CEO says curing certain cancers within a decade is realistic Bullish
Jun 14, 2026
Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained Bullish
Jun 13, 2026
Is Johnson & Johnson (JNJ) A Good Stock To Buy Now? Bullish
Jun 12, 2026
Johnson & Johnson Just Paid $1 Billion for a Technology That Could … Bullish
Jun 10, 2026
Jim Cramer Applauds Johnson & Johnson’s “Great New Drug Profits, Triple-A Balance … Bullish
Jun 05, 2026
Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations Bullish
Jun 02, 2026
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why … Neutral
May 29, 2026
Is Johnson & Johnson Stock Outperforming the Dow? Neutral
May 22, 2026
Johnson & Johnson (JNJ) Unveils Next‑Gen Catheter for Coronary Artery Disease Bullish
May 13, 2026
An unloved health-care stock gets a welcome nod in this AI-obsessed market Bullish
May 05, 2026
Johnson & Johnson reaches a milestone for one of its most exciting … Bullish
May 04, 2026
Johnson & Johnson’s (JNJ) Accelerating Growth Justifies the Higher Multiple Bullish
May 03, 2026
Jim Cramer Shares Key Trend For Johnson & Johnson (JNJ) Shares Bullish
Apr 26, 2026
Johnson & Johnson AGM: CEO Duato touts “catalyst year,” 5.3% sales growth … Bullish
Apr 24, 2026
Is Johnson & Johnson (JNJ) a Buy on Sales Growth and Solid … Bullish
Apr 14, 2026
Jim Cramer on Johnson & Johnson: “If It Gets Blasted, Try to … Bullish
Apr 13, 2026
Johnson & Johnson (JNJ) is Gaining from Its Strong Innovative Medicine Growth Bullish
Apr 10, 2026
Could Buying This Dividend Pharma Stock Today Set You Up for Life? Bullish
Apr 08, 2026
We're exiting our position in a drug stock and initiating a stake … Bullish
Mar 31, 2026
The Dividend King That's Raised Its Payout for 63 Consecutive Years Bullish

Related Articles

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Yahoo Finance · Jul 15, 2026
Neutral

Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of …

Nasdaq · Jun 12, 2026
Bearish

Johnson & Johnson (JNJ) Unveils Next‑Gen Catheter for Coronary Artery Disease

Yahoo Finance · May 22, 2026
Neutral

An unloved health-care stock gets a welcome nod in this AI-obsessed market

CNBC · May 13, 2026
Mixed

Johnson & Johnson AGM: CEO Duato touts “catalyst year,” 5.3% sales growth and $32B investment …

Yahoo Finance · Apr 26, 2026
Mixed

We're exiting our position in a drug stock and initiating a stake in a more …

CNBC · Apr 08, 2026
Mixed
🤖

AI Overview

PARAGRAPH 1 --- Johnson & Johnson (JNJ) reported strong Q2 2026 results, with sales up 6.6% YoY to $25.31B, driven by growth in immunology drug Tremfya and cancer treatment Darzalex. Adjusted EPS was $2.90, surpassing estimates. The company raised its full-year guidance and increased its dividend for the 64th consecutive year.

PARAGRAPH 2 --- The healthcare sector was positively impacted, with JNJ's stock price surging following the earnings beat. Competitors like Medtronic and Danaher also saw positive momentum. Investors rotated into JNJ, seeking stable earnings growth and a solid dividend, pushing the stock up 61% over the past year.

PARAGRAPH 3 --- Next, watch for JNJ's Q3 2026 earnings release on October 15, 2026, to see if the company maintains its strong performance. Additionally, monitor the FDA's decision on JNJ's potential new drug, apalutamide, expected by December 2026, which could further boost the company's growth pipeline.
AI Overview as of Aug 12, 2026

Timeline

First SeenMar 31, 2026
Last UpdatedAug 21, 2026